Literature DB >> 27144058

Current practices and guidelines for clinical next-generation sequencing oncology testing.

Samuel P Strom1.   

Abstract

Next-generation sequencing (NGS) has been rapidly integrated into molecular pathology, dramatically increasing the breadth genomic of information available to oncologists and their patients. This review will explore the ways in which this new technology is currently applied to bolster care for patients with solid tumors and hematological malignancies, focusing on practices and guidelines for assessing the technical validity and clinical utility of DNA variants identified during clinical NGS oncology testing.

Entities:  

Keywords:  Cancer genomics; molecular diagnostics; next-generation sequencing

Year:  2016        PMID： 27144058      PMCID： PMC4850126          DOI： 10.28092/j.issn.2095-3941.2016.0004

Source DB:  PubMed          Journal:  Cancer Biol Med        ISSN： 2095-3941            Impact factor:   4.248


  29 in total

1.  Somatic mosaicism of a CDKL5 mutation identified by next-generation sequencing.

Authors:  Takeshi Kato; Naoya Morisada; Hiroaki Nagase; Masahiro Nishiyama; Daisaku Toyoshima; Taku Nakagawa; Azusa Maruyama; Xue Jun Fu; Kandai Nozu; Hiroko Wada; Satoshi Takada; Kazumoto Iijima
Journal:  Brain Dev       Date:  2015-03-27       Impact factor: 1.961

2.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

3.  The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Ondrej Fiala; Milos Pesek; Jindrich Finek; Lucie Benesova; Barbora Belsanova; Marek Minarik
Journal:  Cancer Genet       Date:  2013-01-10

4.  The development of next-generation sequencing assays for the mitochondrial genome and 108 nuclear genes associated with mitochondrial disorders.

Authors:  Shale Dames; Lan-Szu Chou; Ye Xiao; Tyler Wayman; Jennifer Stocks; Marc Singleton; Karen Eilbeck; Rong Mao
Journal:  J Mol Diagn       Date:  2013-05-09       Impact factor: 5.568

5.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

6.  Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.

Authors:  Holly LaDuca; A J Stuenkel; Jill S Dolinsky; Steven Keiles; Stephany Tandy; Tina Pesaran; Elaine Chen; Chia-Ling Gau; Erika Palmaer; Kamelia Shoaepour; Divya Shah; Virginia Speare; Stephanie Gandomi; Elizabeth Chao
Journal:  Genet Med       Date:  2014-04-24       Impact factor: 8.822

7.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

8.  Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.

Authors:  Nicky D'Haene; Marie Le Mercier; Nancy De Nève; Oriane Blanchard; Mélanie Delaunoy; Hakim El Housni; Barbara Dessars; Pierre Heimann; Myriam Remmelink; Pieter Demetter; Sabine Tejpar; Isabelle Salmon
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

9.  Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis.

Authors:  Clare M McCourt; Darragh G McArt; Ken Mills; Mark A Catherwood; Perry Maxwell; David J Waugh; Peter Hamilton; Joe M O'Sullivan; Manuel Salto-Tellez
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

10.  Assessing the necessity of confirmatory testing for exome-sequencing results in a clinical molecular diagnostic laboratory.

Authors:  Samuel P Strom; Hane Lee; Kingshuk Das; Eric Vilain; Stanley F Nelson; Wayne W Grody; Joshua L Deignan
Journal:  Genet Med       Date:  2014-01-09       Impact factor: 8.822
View more
  38 in total

1.  Variant Review with the Integrative Genomics Viewer.

Authors:  James T Robinson; Helga Thorvaldsdóttir; Aaron M Wenger; Ahmet Zehir; Jill P Mesirov
Journal:  Cancer Res       Date:  2017-11-01       Impact factor: 12.701

Review 2.  The Architecture of a Precision Oncology Platform.

Authors:  Alessandro Laganà
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 3.  Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies.

Authors:  Himachandana Atluri; Yoheved S Gerstein; Courtney D DiNardo
Journal:  Curr Hematol Malig Rep       Date:  2022-10-24       Impact factor: 4.213

4.  Increased number of subclones in lung squamous cell carcinoma elicits overexpression of immune related genes.

Authors:  Myung Jin Song; Sang Hoon Lee; Eun Young Kim; Yoon Soo Chang
Journal:  Transl Lung Cancer Res       Date:  2020-06

5.  A machine learning approach for somatic mutation discovery.

Authors:  Derrick E Wood; James R White; Andrew Georgiadis; Beth Van Emburgh; Sonya Parpart-Li; Jason Mitchell; Valsamo Anagnostou; Noushin Niknafs; Rachel Karchin; Eniko Papp; Christine McCord; Peter LoVerso; David Riley; Luis A Diaz; Siân Jones; Mark Sausen; Victor E Velculescu; Samuel V Angiuoli
Journal:  Sci Transl Med       Date:  2018-09-05       Impact factor: 17.956

6.  Qualitative and quantitative assessment of Illumina's forensic STR and SNP kits on MiSeq FGx™.

Authors:  Vishakha Sharma; Hoi Yan Chow; Donald Siegel; Elisa Wurmbach
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

Review 7.  Molecular Testing of Brain Tumor.

Authors:  Sung-Hye Park; Jaekyung Won; Seong-Ik Kim; Yujin Lee; Chul-Kee Park; Seung-Ki Kim; Seung-Hong Choi
Journal:  J Pathol Transl Med       Date:  2017-05-12

8.  Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.

Authors:  Aino Paasinen-Sohns; Viktor H Koelzer; Angela Frank; Julian Schafroth; Aline Gisler; Melanie Sachs; Anne Graber; Sacha I Rothschild; Andreas Wicki; Gieri Cathomas; Kirsten D Mertz
Journal:  Neoplasia       Date:  2017-02-03       Impact factor: 5.715

9.  Next Generation Sequencing: From Research Area to Clinical Practice.

Authors:  Chiara Di Resta; Maurizio Ferrari
Journal:  EJIFCC       Date:  2018-11-07

Review 10.  The Application of Control Materials for Ongoing Quality Management of Next-Generation Sequencing in a Clinical Genetic Laboratory.

Authors:  Young-Kyu Min; Kyung-Sun Park
Journal:  Medicina (Kaunas)       Date:  2021-05-28       Impact factor: 2.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.